Bempedoic acid is an effective option for some statin-intolerant patients with an elevated predicted risk of cardiovascular events. However, as JAMA Executive Editor Gregory Curfman, MD, discusses with editorialist Dhruv S. Kazi, MD, MSc, MS, bempedoic acid should not be considered a substitute for statins, which remain the first-line therapy for primary prevention. Related Content:

• Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
• Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular Disease